aDepartment of Pharmaceutical and Health Economics, School of Pharmacy, Leonard Schaeffer Center for Health Policy and Economics
bTitus Family Department of Clinical Pharmacy, School of Pharmacy, University of Southern California, Los Angeles, California
cPolicy and Research Department, Pharmaceutical Research & Manufacturer's of America (PhRMA), Washington, District of Columbia, USA
Correspondence to Xue Han, PhD, Department of Pharmaceutical and Health Economics, School of Pharmacy, Leonard Schaeffer Center for Health Policy and Economics, University of Southern California, 635 Downey Way, VPD 212B, Los Angeles, CA 90089, USA. E-mail: [email protected]
Abbreviations: ACC/AHA, American College of Cardiology/American Heart Association; ACE-I, angiotensin-converting enzyme inhibitors; AMI, acute myocardial infarction; ARB, angiotensin II receptor blockers; CCB, calcium channel blockers; CVD, cardiovascular disease; GLM, generalized linear model
Received 26 June, 2018
Accepted 7 November, 2018